Médunik and Biocodex sign exclusive agreement for Diacomit in Canada

Médunik Canada has entered into an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome.

The post Médunik and Biocodex sign exclusive agreement for Diacomit in Canada appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.